Interleukin 2 News and Research

RSS

Gene expression networks flag potential therapeutic targets for SARS-CoV-2

An international team of researchers from Canada, Australia, the Netherlands, and the United States has identified dozens of genes that could contribute to the pathology of coronavirus disease 2019 (COVID-19) and serve as potential therapeutic targets.

7 Jul 2020

Inflammatory changes in tumors can cause drug resistance in cancer blood vessels

Scientists at Hokkaido University and collaborators have identified how inflammatory changes in tumors caused by chemotherapy trigger blood vessel anomalies and thus drug-resistance, resulting in the poor prognosis of cancer patients.

1 Jul 2020

BMI should be assessed in management of COVID-19 patients

A new study published on the preprint server medRxiv* in June 2020 reports that obesity is a risk factor of composite poor outcome of COVID-19 disease. On the other hand, COVID-19 patients with 'composite poor outcome' have higher BMI. Therefore, BMI should be assessed in the management of COVID-19 patients, and special attention should be given to patients with obesity.

1 Jul 2020

Oral hygiene and severity of COVID-19 – the connection

Their study titled, “Could there be a link between oral hygiene and the severity of SARS-CoV-2 infections?” was published in the latest issue of the journal British Dental Journal.

30 Jun 2020

Pediatric patients more resilient against COVID-19 compared to adults

The majority of children with COVID-19 in 26 countries fared well clinically compared to adults during the first four months of the pandemic, a newly released study shows.

26 Jun 2020

Study identifies new allergy pathway

Researchers at Johns Hopkins Bloomberg School of Public Health have identified the sequence of molecular events by which tiny, tick-like creatures called house dust mites trigger asthma and allergic rhinitis.

25 Jun 2020

Research team profiles the body's immune response to COVID-19

A team from Lawson Health Research Institute and Western University are the first in the world to profile the body's immune response to COVID-19.

25 Jun 2020

Protein profile in serum reflects COVID-19 severity

The wide range of manifestations of COVID-19 has continued to baffle investigators. Now, a new study published on the preprint server medRxiv in June 2020 shows that blood proteins in COVID-19 patients change over time, and these can possibly predict or reflect the severity of disease. More, they may present targets for treatment.

25 Jun 2020

UTHealth tests arthritis drug's effect on COVID-19-induced cytokine storm

A drug is being studied for its effectiveness in treating a type of severe immune overreaction seen in patients with COVID-19-induced pneumonia by researchers at The University of Texas Health Science Center at Houston.

22 Jun 2020

Dust mite allergens activate well-known inflammatory factor to trigger allergies

A research team at MedUni Vienna, working in cooperation with the Johns Hopkins University in Baltimore, has discovered how certain dust mite allergens activate a well-known inflammatory factor - serum amyloid A protein -and can thus "trim" the lung tissue "in the direction of allergy".

22 Jun 2020

Repurposing immunosuppressants to manage COVID-19

It might seem paradoxical to suggest immunosuppression could play a role in managing COVID-19. The seemingly logical therapeutic option for this disease would be an antiviral.

18 Jun 2020

Exposure to certain e-cig cartridges may cause fatal lung damage

Researchers at the University of Rochester Medical Center, New York, have shown that long-term exposure to certain electronic nicotine delivery systems (ENDS) may cause lung toxicity and injury among vapers.

16 Jun 2020

Study shows how combining two drugs may be an effective treatment for HLH

Scientists at St. Jude Children's Research Hospital, UCSF Benioff Children's Hospitals and Baylor College of Medicine are investigating how to best treat hemophagocytic lymphohistiocytosis (HLH), a rare immune disorder.

12 Jun 2020

Damon Runyon Cancer Research Foundation awards $3.2 million to early-career physician-scientists

The Damon Runyon Cancer Research Foundation has named four new Damon Runyon Clinical Investigators.

12 Jun 2020

Progression and severity of COVID-19 highly dependant on cytokine changes

A new review paper by the researchers from Spain, published in the journal Cytokine & Growth Factor Reviews, demonstrates how changes in the levels of cytokines and other biomolecules are associated with the presence and more serious prognosis of coronavirus disease (COVID-19).

11 Jun 2020

Females mount stronger T-cell response to SARS-CoV-2

A new study published on the preprint server medRxiv in June 2020 shows that immune cells, antibody levels, cytokine levels, and viral loads contribute to the sex difference seen in response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

10 Jun 2020

Anticardiolipin antibodies and COVID-19

A new study has shown that anticardiolipin antibodies are associated with the novel coronavirus infection or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes COVID-19.

10 Jun 2020

A drug to treat harsh complications of coronavirus infection is registered in Russia

Levilimab received state approval through a fast-track mechanism, according to Decree No. 441 of the Government of the Russian Federation of April 4, 2020, since its mechanism of action is associated with the control of the cytokine storm, which is one of the manifestations of coronavirus infection.

9 Jun 2020

Kidney enzyme renalase a potential therapy for severe COVID-19

Researchers from Yale School of Medicine have discovered that a low blood level of an enzyme called renalase is associated with severe coronavirus disease 2019 (COVID-19).

7 Jun 2020

New approach helps identify protein biomarkers in the blood of COVID-19 patients

People respond very differently to infection with the novel coronavirus (SARS-CoV-2). While some patients develop no symptoms at all, others will develop severe disease and may even die. For this reason, there is an urgent need for 'biomarkers', quantifiable biological characteristics which could provide a reliable means of predicting disease progression and severity.

5 Jun 2020